Biosurgery is a leading developer of novel biotherapeutic and biomaterial products. Our products and research pipeline harness the power of biology to improve the health of patients in the orthopaedics and post-surgical adhesive disease areas.

Genzyme's rich scientific and clinical experience has enabled us to develop leading programs in biomaterials and cell therapy for new disease areas. The result: a suite of products and product development candidates designed to provide new tools to help improve patient outcomes, reduce the time and complications associated with surgery, and may in some cases, postpone the need for surgery. 

One of the world's foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $3 billion and more than 9,000 employees in locations spanning the globe.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences to address a range of unmet medical needs. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial research and development program focused on genetic diseases, immune system disorders, heart disease, and cancer.